# Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

> **NCT04004208** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 113 (actual)

## Conditions studied

- Retinopathy of Prematurity (ROP)

## Interventions

- **DRUG:** Eylea (Aflibercept, BAY86-5321)
- **PROCEDURE:** Laser photocoagulation

## Key facts

- **NCT ID:** NCT04004208
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-25
- **Primary completion:** 2021-02-12
- **Final completion:** 2021-02-12
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2022-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004208, "Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04004208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*